- Home
- NRIX vs ACHR Comparison
NRIX vs ACHR Comparison
Compare NRIX & ACHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- ACHR
- Stock Information
- Founded
- NRIX 2009
- ACHR 2018
- Country
- NRIX United States
- ACHR United States
- Employees
- NRIX N/A
- ACHR N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- ACHR Aerospace
- Sector
- NRIX Health Care
- ACHR Industrials
- Exchange
- NRIX Nasdaq
- ACHR Nasdaq
- Market Cap
- NRIX 1.3B
- ACHR 1.3B
- IPO Year
- NRIX 2020
- ACHR N/A
- Fundamental
- Price
- NRIX $19.83
- ACHR $9.51
- Analyst Decision
- NRIX Strong Buy
- ACHR Strong Buy
- Analyst Count
- NRIX 17
- ACHR 8
- Target Price
- NRIX $30.29
- ACHR $10.63
- AVG Volume (30 Days)
- NRIX 988.4K
- ACHR 56.7M
- Earning Date
- NRIX 02-13-2025
- ACHR 11-07-2024
- Dividend Yield
- NRIX N/A
- ACHR N/A
- EPS Growth
- NRIX N/A
- ACHR N/A
- EPS
- NRIX N/A
- ACHR N/A
- Revenue
- NRIX $56,424,000.00
- ACHR N/A
- Revenue This Year
- NRIX N/A
- ACHR N/A
- Revenue Next Year
- NRIX $3.79
- ACHR $2,632.29
- P/E Ratio
- NRIX N/A
- ACHR N/A
- Revenue Growth
- NRIX N/A
- ACHR N/A
- 52 Week Low
- NRIX $7.65
- ACHR $2.82
- 52 Week High
- NRIX $29.56
- ACHR $10.58
- Technical
- Relative Strength Index (RSI)
- NRIX 38.42
- ACHR 66.53
- Support Level
- NRIX $19.38
- ACHR $6.85
- Resistance Level
- NRIX $21.67
- ACHR $10.58
- Average True Range (ATR)
- NRIX 1.34
- ACHR 1.06
- MACD
- NRIX 0.00
- ACHR 0.02
- Stochastic Oscillator
- NRIX 12.61
- ACHR 75.23
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
About ACHR Archer Aviation Inc.
Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner.